Johnson & Johnson is to expand its offering of products used to treat haemorrhagic and ischaemic stroke by purchasing Micrus Endovascular for around $480m. Micrus will add neurointerventional technology to J&J’s existing neuro portfolio, including enhanced bioactive ...
Please Login to read the full article.
